

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-2. (cancelled).

3. (currently amended): A method for treating cancer, comprising administering to a patient in need of said treatment

(i) macrophages having at least one of the following properties:

- their cytotoxic activity without IFN- $\gamma$  is increased by about 20 to 30% with respect to standard macrophages;

- their cytotoxic activity with IFN- $\gamma$  is increased by about 20 to about 40% with respect to standard macrophages incubated with IFN- $\gamma$ ;

- deactivation of the cytotoxic activity following activation of IFN- $\gamma$  is such that sixty hours after activation with IFN- $\gamma$ , the residual cytotoxic activity is at least 30% of the maximum cytotoxic activity presented by the macrophages due to IFN- $\gamma$  activation, with said cytotoxic activity being measured as a percentage of the inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells; and

(ii) bispecific antibodies which recognize both a) an antigen of said macrophages, and b) an antigen of a tumoral cell to be targeted by said macrophages.

4. (previously presented): The method according to claim 3, wherein the macrophages are injected at the same time as the bispecific antibodies.

5. (previously presented): The method according to claim 3, wherein the bispecific antibodies are preincubated with macrophages before injection.